Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals logoBellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company's CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLCM
  • CUSIP:
Key Metrics:
  • Previous Close: $13.62
  • 50 Day Moving Average: $13.23
  • 200 Day Moving Average: $16.93
  • 52-Week Range: $7.24 - $23.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.53
  • P/E Growth: 0.00
  • Market Cap: $352.37M
  • Outstanding Shares: 27,105,000
  • Beta: 1.48
Profitability:
  • Net Margins: -19,399.12%
  • Return on Equity: -49.65%
  • Return on Assets: -42.92%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 12.41%
  • Quick Ratio: 12.41%
Additional Links:
Companies Related to Bellicum Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Bellicum Pharmaceuticals (NASDAQ:BLCM) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.00 (101.64% upside)

Analysts' Ratings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Show:
DateFirmActionRatingPrice TargetDetails
12/9/2016Cantor FitzgeraldSet Price TargetBuy$32.00View Rating Details
12/5/2016Jefferies Group LLCSet Price TargetBuy$22.00View Rating Details
12/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$29.00View Rating Details
11/30/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$31.00View Rating Details
8/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $31.00View Rating Details
8/9/2016Citigroup Inc.UpgradeNeutral -> Buy$24.00View Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$20.00View Rating Details
9/11/2015GuggenheimUpgradeNeutral -> Buy$38.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/7/2016Q3($0.63)($0.66)$0.09 million$0.11 millionViewN/AView Earnings Details
8/8/2016Q216($0.57)($0.61)$0.06 millionViewListenView Earnings Details
5/9/2016($0.51)($0.44)ViewN/AView Earnings Details
3/14/2016Q415($0.44)($0.63)$2.00 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.38)($0.51)$0.18 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q215($0.49)($0.40)$0.23 million$0.08 millionViewListenView Earnings Details
5/11/2015Q1($0.22)($0.30)$0.11 millionViewN/AView Earnings Details
3/11/2015Q4($11.79)($18.99)$0.02 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Current Year EPS Consensus Estimate: $-2.51 EPS
Next Year EPS Consensus Estimate: $-2.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.50)($0.50)($0.50)
Q2 20162($0.60)($0.59)($0.60)
Q3 20162($0.64)($0.64)($0.64)
Q4 20162($0.67)($0.65)($0.66)
Q1 20171($0.68)($0.68)($0.68)
Q2 20171($0.71)($0.71)($0.71)
Q3 20171($0.75)($0.75)($0.75)
Q4 20171($0.82)($0.82)($0.82)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 68.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Kevin M SlawinDirectorSell30,000$12.54$376,200.00View SEC Filing  
12/15/2016Kevin M SlawinInsiderSell30,000$15.45$463,500.00View SEC Filing  
12/5/2016David M SpencerInsiderSell5,000$20.00$100,000.00View SEC Filing  
12/1/2016Annemarie MoseleyCOOSell25,000$17.54$438,500.00View SEC Filing  
11/28/2016Alan A. MussoCFOSell29,300$19.51$571,643.00View SEC Filing  
9/23/2016Ken MoseleyVPSell11,800$20.10$237,180.00View SEC Filing  
9/23/2016Kevin M SlawinInsiderSell23,416$20.12$471,129.92View SEC Filing  
9/20/2016David M SpencerInsiderSell2,500$20.01$50,025.00View SEC Filing  
9/20/2016Ken MoseleyVPSell2,200$20.01$44,022.00View SEC Filing  
8/15/2016Ken MoseleyVPSell1,000$20.00$20,000.00View SEC Filing  
8/15/2016Kevin M SlawinInsiderSell67,000$19.31$1,293,770.00View SEC Filing  
7/27/2016David M. SpencerInsiderSell10,000$15.00$150,000.00View SEC Filing  
7/18/2016Kevin M SlawinCTOSell2,719$13.99$38,038.81View SEC Filing  
7/15/2016Kevin M SlawinCTOSell22,281$13.72$305,695.32View SEC Filing  
6/2/2016Annemarie MoseleyCOOSell25,000$13.00$325,000.00View SEC Filing  
6/2/2016Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
4/22/2016Kevin M SlawinCTOSell55,000$11.43$628,650.00View SEC Filing  
1/4/2016Annemarie MoseleyCOOSell35,000$19.07$667,450.00View SEC Filing  
12/1/2015David M SpencerInsiderSell5,000$22.95$114,750.00View SEC Filing  
11/24/2015Alan A MussoCFOSell29,300$22.34$654,562.00View SEC Filing  
11/2/2015Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
10/1/2015Thomas J FarrellCEOSell2,500$14.58$36,450.00View SEC Filing  
9/11/2015David M SpencerInsiderSell5,000$19.00$95,000.00View SEC Filing  
9/1/2015Thomas J FarrellCEOSell2,500$16.78$41,950.00View SEC Filing  
7/15/2015Kevin M SlawinCTOSell6,000$20.00$120,000.00View SEC Filing  
6/16/2015David M SpencerInsiderSell20,000$22.96$459,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bellicum Pharmaceuticals (NASDAQ:BLCM)
DateHeadline
streetinsider.com logoBellicum Pharma (BLCM) Begins Patient Dosing with Controllable CAR T-Cell Product Candidate - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - February 21 at 9:32 AM
finance.yahoo.com logoMoving Average Crossover Alert: Bellicum Pharmaceuticals (BLCM) (NASDAQ:BLCM)
finance.yahoo.com - February 13 at 4:27 PM
thestreet.com logo5 Stocks Setting Up for Big Breakouts (NASDAQ:BLCM)
www.thestreet.com - February 7 at 4:55 PM
News IconTrading Watch: FCF and Piotroski Score Check for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - The Tribune (NASDAQ:BLCM)
lakecitytribune.com - February 1 at 4:10 PM
streetinsider.com logoBellicum Pharma (BLCM) Names Rick Fair CEO (NASDAQ:BLCM)
www.streetinsider.com - February 1 at 2:18 AM
News IconStock Vacillating as Volatility Hits a High Point For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Wall Street Beacon (NASDAQ:BLCM)
wsbeacon.com - January 31 at 9:17 PM
bizjournals.com logoHouston pharmaceutical company hires new CEO as it prepares for commercialization - Houston Business Journal (NASDAQ:BLCM)
www.bizjournals.com - January 31 at 9:17 PM
streetinsider.com logoBellicum Pharma (BLCM) Names Rick Fair CEO - StreetInsider.com - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - January 31 at 9:17 PM
finance.yahoo.com logoBellicum Announces Appointment of Rick Fair as Chief Executive Officer in Preparation for Commercialization of BPX-501 and Next Phase of Growth (NASDAQ:BLCM)
finance.yahoo.com - January 31 at 4:13 PM
finance.yahoo.com logo7:13 am Bellicum Pharma appoints Rick Fair as President and CEO, succeeding Tom Farrell, who will serve as an advisor to the co during the transition (NASDAQ:BLCM)
finance.yahoo.com - January 31 at 4:13 PM
bizjournals.com logoHouston pharmaceutical company hires new CEO as it prepares for commercialization (NASDAQ:BLCM)
www.bizjournals.com - January 31 at 4:13 PM
News IconAnalysts Watch Bellicum Pharmaceuticals, Inc. (BLCM) And Issue New Targets (NASDAQ:BLCM)
flapship.com - January 30 at 8:51 PM
News IconAnalysts Watch Bellicum Pharmaceuticals, Inc. (BLCM) And Issue New Targets - NewsDen (NASDAQ:BLCM)
newsden.net - January 30 at 3:49 PM
News IconStock Review: Checking in on Share of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Gilbert Daily (NASDAQ:BLCM)
gilbertdaily.com - January 30 at 3:49 PM
News IconMarket Check: Narrowing in on Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - The Tribune (NASDAQ:BLCM)
lakecitytribune.com - January 30 at 3:49 PM
News IconFCF Score Check on Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - The Tribune (NASDAQ:BLCM)
lakecitytribune.com - January 27 at 9:30 PM
News IconTechnical Updates on Shares of Bellicum Pharmaceuticals Inc. (BLCM) - Market Point (NASDAQ:BLCM)
mtptnews.com - January 26 at 4:37 PM
News IconWhat is the Sell-side Saying About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)? - Aiken Advocate (NASDAQ:BLCM)
aikenadvocate.com - January 25 at 2:31 AM
News IconVC Score In Focus for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - The Tribune (NASDAQ:BLCM)
lakecitytribune.com - January 23 at 8:31 PM
News IconTop Stock With Upside & Growth Potential: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Prospect Journal (NASDAQ:BLCM)
prospectjournal.com - January 23 at 8:31 PM
News IconTrend Strength Monitor on Shares of Bellicum Pharmaceuticals Inc. (BLCM) - Sherwood Daily (NASDAQ:BLCM)
sherwooddaily.com - January 18 at 3:21 PM
News IconShort Interest Alert: Time to Reconsider Bellicum Pharmaceuticals Incorporated (NASDAQ:BLCM) After Less Short ... - Baxley Report (NASDAQ:BLCM)
baxleyreport.com - January 17 at 4:41 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Prospect Journal (NASDAQ:BLCM)
prospectjournal.com - January 16 at 9:01 PM
News IconChecking Indicator Levels for Bellicum Pharmaceuticals Inc. (BLCM) - Springdale Times (NASDAQ:BLCM)
springdaletimes.com - January 16 at 9:01 PM
News IconBellicum Pharmaceuticals Inc BLCM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BLCM)
www.bioportfolio.com - January 13 at 9:35 PM
News IconStock Getting Tripped Up In Session: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Wall Street Beacon (NASDAQ:BLCM)
wsbeacon.com - January 11 at 4:17 PM
capitalcube.com logoETFs with exposure to Bellicum Pharmaceuticals, Inc. : January 6, 2017 (NASDAQ:BLCM)
www.capitalcube.com - January 6 at 4:15 PM
News IconA Look At Cancer Immunotherapy And Some Key Players 2017 (NASDAQ:BLCM)
www.bionapcfa.com - January 3 at 4:38 PM
biz.yahoo.com logoBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events (NASDAQ:BLCM)
biz.yahoo.com - December 21 at 8:36 PM
marketexclusive.com logoHome SEC Filings Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Entry into a Material Definitive... - Market Exclusive (NASDAQ:BLCM)
marketexclusive.com - December 20 at 4:21 PM
News IconBetter Buy: Ionis Pharmaceuticals, Inc. vs. Bellicum Pharmaceuticals (NASDAQ:BLCM)
qctimes.com - December 12 at 4:07 PM
streetinsider.com logoBellicum Pharma (BLCM) Offers BPX-501 Update at ASH 2016 - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - December 7 at 4:33 PM
streetinsider.com logoBellicum Pharma (BLCM) Presented Updated BPX-501 Study Data in PIDs, Hemoglobinopathies at ASH 2016 - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - December 5 at 4:45 PM
streetinsider.com logoBellicum Pharma (BLCM) Announces GoCAR-T and GoTCR Preclinical Presentations ASH Meeting - StreetInsider.com (NASDAQ:BLCM)
www.streetinsider.com - December 5 at 4:45 PM
capitalcube.com logoETFs with exposure to Bellicum Pharmaceuticals, Inc. : December 5, 2016 (NASDAQ:BLCM)
www.capitalcube.com - December 5 at 4:45 PM
finance.yahoo.com logoBellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting (NASDAQ:BLCM)
finance.yahoo.com - December 5 at 4:45 PM
finance.yahoo.com logoBellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual Meeting (NASDAQ:BLCM)
finance.yahoo.com - December 5 at 4:45 PM
us.rd.yahoo.com logo1:39 am Bellicum Pharma reports updated clinical data from BPX-501 study; 35 children are disease- and GvHD-free following haploidentical stem cell transplant with BPX-501 (NASDAQ:BLCM)
us.rd.yahoo.com - December 5 at 10:35 AM
finance.yahoo.com logoBellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies (NASDAQ:BLCM)
finance.yahoo.com - December 3 at 3:45 PM
us.rd.yahoo.com logoCoverage initiated on Bellicum Pharma by Ladenburg Thalmann (NASDAQ:BLCM)
us.rd.yahoo.com - December 1 at 1:56 AM
News IconFollowing the Numbers on Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - The Business Journal (NASDAQ:BLCM)
belmontbusinessjournal.com - November 30 at 3:55 PM
capitalcube.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : November 29, 2016 (NASDAQ:BLCM)
www.capitalcube.com - November 29 at 3:16 PM
News IconInvestor Guide: Check on Technical Levels for Bellicum Pharmaceuticals Inc. (BLCM) - StockTalk Daily (NASDAQ:BLCM)
stocktalkdaily.com - November 23 at 4:01 PM
capitalcube.com logoETFs with exposure to Bellicum Pharmaceuticals, Inc. : November 23, 2016 (NASDAQ:BLCM)
www.capitalcube.com - November 23 at 12:50 PM
News IconBellicum Pharmaceuticals, Inc. BLCM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:BLCM)
www.bioportfolio.com - November 22 at 9:31 PM
News IconTechnical Levels in Review for Bellicum Pharmaceuticals Inc. (BLCM) - StockTalk Daily (NASDAQ:BLCM)
stocktalkdaily.com - November 21 at 3:59 PM
capitalcube.com logoBellicum Pharmaceuticals, Inc. :BLCM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 (NASDAQ:BLCM)
www.capitalcube.com - November 21 at 3:59 PM
News IconFree Cash Flow Score in Focus for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Wall Street Lion (NASDAQ:BLCM)
wslnews.com - November 21 at 8:45 AM
News IconLooking at the Numbers for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) - Marion Business Daily (NASDAQ:BLCM)
marionbusinessdaily.com - November 18 at 8:15 PM
News IconBellicum Pharmaceuticals, Inc.'s (BLCM): Keep an eye on Active stock of Yesterday - Hot Stocks Point (NASDAQ:BLCM)
www.hotstockspoint.com - November 18 at 8:15 PM

Social

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Where is Bellicum Pharmaceuticals' stock going? Where will Bellicum Pharmaceuticals' stock price be in 2017?

7 brokerages have issued twelve-month target prices for Bellicum Pharmaceuticals' stock. Their predictions range from $20.00 to $32.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $27.00 in the next year.

When will Bellicum Pharmaceuticals announce their earnings?

Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

Who owns Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (12.67%), Franklin Resources Inc. (2.40%), State Street Corp (1.20%), Eventide Asset Management LLC (0.92%), Renaissance Technologies LLC (0.31%) and Fred Alger Management Inc. (0.17%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Annemarie Moseley, David M Spencer, Ken Moseley, Kevin M Slawin and Thomas J Farrell.

Who sold Bellicum Pharmaceuticals stock? Who is selling Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC and Fred Alger Management Inc.. Company insiders that have sold Bellicum Pharmaceuticals stock in the last year include Alan A Musso, Annemarie Moseley, David M Spencer, Ken Moseley and Kevin M Slawin.

Who bought Bellicum Pharmaceuticals stock? Who is buying Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Renaissance Technologies LLC, Allianz Asset Management AG and State Street Corp.

How do I buy Bellicum Pharmaceuticals stock?

Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bellicum Pharmaceuticals stock cost?

One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $13.39.

Bellicum Pharmaceuticals (NASDAQ:BLCM) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Earnings History Chart

Earnings by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Dividend History Chart

Dividend Payments by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Last Updated on 2/22/2017 by MarketBeat.com Staff